Hikaru Saito
InvestorPartner at Saisei Ventures
Palo Alto, California
Writes $100K – $5M checks · typically $1.5M
Find your path to Hikaru
104 people in our graph share verified history with Hikaru — schools, employers, funds. One of them is your warm intro.
About
Hikaru Saito is a Partner at Saisei Ventures with a background spanning academic research and pharmaceutical development. He earned a Ph.D. focusing on multidrug resistance in anti-tumor agents, collaborated on patented compound screening with Nihon Chemiphar, and spent six years as a scientist at Astellas developing small molecule formulations and biologics. He subsequently transitioned to business development and venture capital, serving at Astellas Venture Management in Silicon Valley where he evaluated opportunities across RNA, cell, and gene therapy, led deal processes globally, and established partnerships with venture capital funds and research institutions.
Experience
- Saisei VenturesPartnercurrent2023 — presentTokyo, Japan
- Surzen BiotherapeuticsFounding team and directorcurrent2025 — presentTokyo, Japan
- Akatsuki Therapeutics Inc.Founding team and directorcurrent2025 — presentTokyo, Japan
- Senno Therapeutics Inc.Co-founder and Board of Directorscurrent2024 — presentTokyo, Japan
- United Immunity, Co., Ltd.Board of Directorscurrent2023 — presentTokyo, Japan
- ProcellCure, IncMember Board of Directorscurrent2023 — presentKobe, Japan
- eNK Therapeutics, Inc.Member Board of Directors2023 — 2025Tokyo, Japan
- Astellas PharmaSenior Manager, Transaction, Business Development2022Tokyo, Japan
- Catamaran BioBoard Observer2020 — 2022
- Twentyeight-Seven TherapeuticsBoard Observer2020 — 2022Watertown, Massachusetts, United States
- Astellas Venture Management LLCSenior Investment Manager2017 — 2022Menlo Park, California, United States
- Cleave Therapeutics, Inc.Board Observer2019 — 2021San Francisco, California
- TScan TherapeuticsBoard Observer2019 — 2021Waltham, Massachusetts
- Pykus TherapeuticsBoard Observer2018 — 2021Cambridge, Massachusetts, United States
- Astellas PharmaSenior Manager, Innovation & Incubation Research Labs.,Drug Discovery Research2017Tsukuba-shi, Ibaraki
- Astellas PharmaSenior Manager, Innovation Management2015 — 2017Tokyo, Tokyo, Japan
- Astellas PharmaResearcher at Pharmaceutical Research and Technology Labs2013 — 2015Shizuoka, Shizuoka, Japan
- Astellas PharmaResearcher at Pharmaceutical Research and Technology Labs2010 — 2013Shizuoka, Shizuoka, Japan
- Japan Society for the Promotion of ScienceResearch Fellow2008 — 2010Tokyo Institute of Technology
Skills & more
Languages 日本語 · 英語
- 第1種放射線取扱主任者(License for Type-I radiation protection supervisor) — 文部科学省
From Hikaru's professional profile.
Colleagues at Saisei Ventures
Frequently asked questions
- Who is Hikaru Saito?
- Hikaru Saito is a Partner at Saisei Ventures with a background spanning academic research and pharmaceutical development. He earned a Ph.D. focusing on multidrug resistance in anti-tumor agents, collaborated on patented compound screening with Nihon Chemiphar, and spent six years as a scientist at Astellas developing small molecule formulations and biologics. He subsequently transitioned to business development and venture capital, serving at Astellas Venture Management in Silicon Valley where he evaluated opportunities across RNA, cell, and gene therapy, led deal processes globally, and established partnerships with venture capital funds and research institutions.
- Where does Hikaru Saito work?
- Hikaru Saito is Partner at Saisei Ventures.
- What check size does Hikaru Saito write?
- Hikaru Saito typically writes checks of $100K – $5M.
- Where did Hikaru Saito go to school?
- Hikaru Saito studied at Tokyo Institute of Technology (Doctor of Philosophy (PhD), Biomolecular Engineering); The University of Tokyo (Biochemistry and Sructural Biology); The University of Texas M.D. Anderson Cancer Center (Biochemistry and Molecular Biology).
Same school
Also attended Tokyo Institute of Technology25
+ 19 more
Also attended The University of Tokyo197
+ 191 more





























